Key Takeaways United Therapeutics' TETON-2 study showed Tyvaso improved lung function in IPF patients.Benefits were consistent across subgroups, with safety aligning with prior Tyvaso studies.UTHR plans FDA talks this year, with TETON-1 study results expected in early 2026.United Therapeutics (UTHR) remains poised to expand Tyvaso’s label in the respiratory disease space. It recently unveiled results from the late-stage TETON-2 study, which showed clinical benefit in idiopathic pulmonary fibrosis (IPF) pati ...